{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-042322","form_type":"8-K","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.683864+00:00","generated_at":"2026-06-02T02:28:08.950882+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Virpax Q1 2024 operating loss $3.2M, cash $1.9M; Probudur study shows tolerability","bullets":["Operating loss of $3.2M compares to $1.5M in Q1 2023, driven by higher G&A and R&D spend.","Cash at March 31, 2024 was approximately $1.9M.","Probudur maximum tolerated dose study: all doses well-tolerated, no noteworthy effects on body weight or clinical parameters.","Litigation settlement with Sorrento Therapeutics approved by bankruptcy court; initial payment made March 18, 2024.","Pilot study of Probudur in rat model showed reduction in incision-induced pain behaviors."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-042322","json":"https://secwatch.observer/filing/0001213900-24-042322.json","markdown":"https://secwatch.observer/filing/0001213900-24-042322.md","text":"https://secwatch.observer/filing/0001213900-24-042322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024042322/0001213900-24-042322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024042322/ea0205936-8k_virpax.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:28:08.950882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9dad0fa01c3668a448dd5d8c3fe3163dfaecb0c","claim":"Virpax Pharmaceuticals, Inc. reported financial results for the three months ended March 31, 2024.","evidence_excerpt":"Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024042322/0001213900-24-042322-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}